Autoimmune

Voclosporin, the first FDA-approved oral therapy for lupus nephritis, will be sold as Lupkynis by Aurinia Pharmaceuticals and is approved for use in conjunction with immunosuppressive treatment.

Patients with psoriasis may be more likely to have additional autoimmune disorders, including vitiligo, diabetes, autoimmune thyroiditis, rheumatoid arthritis, and inflammatory bowel disease.

Previous studies have shown conflicting characteristic thermographic patterns of the feet in patients with active rheumatoid arthritis (RA). This study probed whether the thermal characteristics of the feet of patients in remission differ to those of healthy controls.

Previous studies have suggested that inflammatory diseases such as rheumatoid arthritis (RA) can increase the risk for dementia and that tumor necrosis factor agents may have a role in preventing the incidence of dementia.

Immunosuppressed patients who had an autoimmune disease (AD) were significantly less likely to develop severe acute respiratory distress syndrome (ARDS) compared with patients who were not immunosuppressed and did not have an AD.

Researchers explored the risk of cardiovascular disease (CVD) as it relates to factors like excess weight, disease evolution time, and clinical activity.

Compared with adalimumab, sarilumab elicited greater improvements in health-related quality of life (QoL), particularly in patients with high levels of interleukin-6 (IL-6).

Despite progress from disease-modifying antirheumatic drugs, there is still a far greater long-term risk of undergoing total knee and hip arthroplasties in patients with rheumatoid arthritis.

Most people with systemic lupus erythematosus and inflammatory arthritis, who use medications that make them immunosuppressed, are not necessarily at greater risk of hospitalization from coronavirus disease 2019 (COVID-19), according to 2 studies.

In a Complete Response Letter, FDA is requesting additional data from Gilead Sciences for its investigational treatment for moderately to severely active rheumatoid arthritis (RA).

Sanofi and Johnson & Johnson are making moves to expand their autoimmune portfolios with recently announced acquisitions.

A new study of patients with rheumatoid arthritis (RA) in Korea has shown that only about half of patients with RA who attained clinical remission were also in imaging remission.

Patients with connective tissue diseases are at greater risk for severe coronavirus disease 2019 (COVID-19) than patients with chronic inflammatory arthritis.

A new study in PLOS ONE has highlighted the broad impact fatigue can have on patients with rheumatoid arthritis (RA), psoriatic arthritis, and axial spondyloarthritis.

Despite concerns, legislation to cap out-of-pocket payments for specialty drugs has not been shown to shift costs to health plans, thereby increasing insurance premiums, according to a study published in New England Journal of Medicine.

Transferring from pediatric to adult care can result in difficulties for patients with childhood-onset systemic lupus erythematosus.

Comorbidities are common in patients with rheumatoid arthritis, and the presence of comorbidities reduces the chance of remission and is associated with worse functional status and disease activity measures.

Promoting engagement in physical activity in early rheumatoid arthritis (RA) can provide small benefits, according to results from a proof of concept study published in Musculoskeletal Care.

Research identified a new type of cell that is in the blood during the period before a rheumatoid arthritis flare and may be used to predict a flare in the weeks before one occurs, according to research published in New England Journal of Medicine.

Two abstracts presented at the European Hematology Association's annual meeting evaluated the frequency of myeloid malignancies in patients with autoimmune disease and the impact autoimmune diseases have on patients with sickle cell disease.

Patients with systemic lupus erythematosus (SLE) may consider hydroxychloroquine essential to their treatment, but after the drug was identified as a potential therapy for coronavirus disease 2019 (COVID-19), patients with SLE experienced reduced access to the treatment, which could increase the risk of SLE flare.

Researchers identified a protein that can not only worsen skin inflammation but also plays a key role in damaging joints and bones of patients with psoriasis.

Though rare, patients with both autoimmune hemolytic anemia (AHIA) and non-Hodgkin lymphoma face stark odds of long-term survival. A new study lends insights into how to best diagnose and treat those patients.

FDA recently accepted the Biologics Licensing Application for inebilizumab to treat a rare autoimmune condition, neuromyelitis optica spectrum disorder. The results for inebilizumab were presented at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.

Commercial health plan initiation of a co-pay accumulator adjustment program for specialty medications treating autoimmune diseases was associated with significant reductions in medication adherence and persistence.

In rare cases, despite being on antiretroviral therapy and being virally suppressed, patients experience extreme immune decline.